TradeMore
2021-11-12
Correct
3 Stocks Than Can Turn $10,000 Into $50,000 by 2025<blockquote>到2025年可以将10,000美元变成50,000美元的3只股票</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":879111551,"tweetId":"879111551","gmtCreate":1636689259966,"gmtModify":1636689260084,"author":{"id":4097720712211120,"idStr":"4097720712211120","authorId":4097720712211120,"authorIdStr":"4097720712211120","name":"TradeMore","avatar":"https://static.tigerbbs.com/976c10f5e71e9a3b002205015f764d44","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":21,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Correct </p></body></html>","htmlText":"<html><head></head><body><p>Correct </p></body></html>","text":"Correct","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/879111551","repostId":1148636425,"repostType":4,"repost":{"id":"1148636425","kind":"news","pubTimestamp":1636686971,"share":"https://www.laohu8.com/m/news/1148636425?lang=zh_CN&edition=full","pubTime":"2021-11-12 11:16","market":"us","language":"en","title":"3 Stocks Than Can Turn $10,000 Into $50,000 by 2025<blockquote>到2025年可以将10,000美元变成50,000美元的3只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1148636425","media":"Motley Fool","summary":"Key Points\n\nTeladoc’s revenue and patient visits this year show it isn't a pandemic-only stock.\nVert","content":"<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul> <li>Teladoc’s revenue and patient visits this year show it isn't a pandemic-only stock.</li> <li>Vertex plans to file for regulatory approval next year of a potentially game-changing blood disorder candidate.</li> <li>Etsy’s recent acquisitions should help it to expand its reach and grow in the coming years.</li> </ul> A lot can happen in five years. And that's exactly why it's a great idea to hold stocks for that period of time. This way, you have the opportunity to benefit from a company's growing sales, new products, or expansion into additional markets. Often, a company's good news takes a while to translate into share gains.</p><p><blockquote><ul><li>Teladoc今年的收入和患者就诊次数表明，它并不是一只只针对大流行的股票。</li><li>Vertex计划明年向监管部门申请一种可能改变游戏规则的血液疾病候选药物的批准。</li><li>Etsy最近的收购应该有助于其扩大业务范围并在未来几年实现增长。</li></ul>五年内会发生很多事情。这就是为什么在这段时间内持有股票是个好主意。这样，你就有机会从公司不断增长的销售额、新产品或向其他市场的扩张中受益。通常，公司的好消息需要一段时间才能转化为股价上涨。</blockquote></p><p> The following two healthcare stocks and one consumer stock have what it takes to produce lasting revenue growth in the coming five years -- and eventually, major share-price gains. That means they very well might turn $10,000 into $50,000.</p><p><blockquote>以下两只医疗保健股和一只消费股有能力在未来五年内实现持久的收入增长，并最终实现股价大幅上涨。这意味着他们很可能会把10,000美元变成50,000美元。</blockquote></p><p> The pandemic equaled meteoric growth for <b>Teladoc Health</b></p><p><blockquote>这场大流行相当于<b>Teladoc健康</b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/016a56aa1f203a6ad80617c0119f66cf\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> As vaccinations took off and the pandemic eased, investors worried business at Teladoc would drop. And that's why the shares have suffered this year -- falling 28% so far.</p><p><blockquote>随着疫苗接种的开始和疫情的缓解，投资者担心Teladoc的业务会下降。这就是该股今年遭受重创的原因——迄今为止已下跌28%。</blockquote></p><p> But Teladoc is proving that it isn't a pandemic-only stock. People have returned to work, and healthcare facilities have returned to normal operations -- yet Teladoc's revenue and patient visits still are climbing.</p><p><blockquote>但Teladoc正在证明它不仅仅是一只只针对大流行的股票。人们已经重返工作岗位，医疗机构也已恢复正常运营，但Teladoc的收入和患者就诊人数仍在攀升。</blockquote></p><p> In the most recent earnings report, Teladoc said quarterly revenue rose 81% and patient visits increased 37%, surpassing 3.9 million. The company even increased the lower end of its annual revenue guidance. It expects a minimum of $2.015 billion in revenue this year, and next year's revenue may reach $2.6 billion.</p><p><blockquote>Teladoc在最新的收益报告中表示，季度收入增长了81%，患者访问量增长了37%，超过390万人次。该公司甚至提高了年度收入指引的下限。它预计今年的营收至少为20.15亿美元，明年的营收可能达到26亿美元。</blockquote></p><p> Teladoc's strength in chronic-care management should be a key element driving future patient loyalty and growth. Today, 24% of Teladoc's chronic-care members are enrolled in multiple programs. That number was only 8% a year ago.</p><p><blockquote>Teladoc在慢性护理管理方面的优势应该成为推动未来患者忠诚度和增长的关键因素。如今，Teladoc 24%的慢性护理会员参加了多个计划。一年前这个数字只有8%。</blockquote></p><p> All of these numbers together show us that Teladoc's success last year wasn't just a one-off. Instead, it was the first chapter in a much longer story.</p><p><blockquote>所有这些数字加在一起向我们表明，Teladoc去年的成功不仅仅是一次性的。相反，这是一个更长故事的第一章。</blockquote></p><p> <b>Vertex Pharmaceuticals</b></p><p><blockquote><b>顶点制药</b></blockquote></p><p> Why should we be optimistic about Vertex? First, the company makes billions of dollars in revenue and profit annually from its portfolio of cystic fibrosis (CF) drugs.</p><p><blockquote>为什么要看好Vertex？首先，该公司每年从其囊性纤维化(CF)药物组合中获得数十亿美元的收入和利润。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/86204fd33911338b208591a6f1f67d95\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> It's the worldwide CF leader and expects that to continue until at least the late 2030s.</p><p><blockquote>它是全球CF领导者，预计这种情况至少会持续到2030年代末。</blockquote></p><p> That said, investors worry Vertex is struggling to expand beyond CF. Recent news indicates this view may be overly pessimistic. This year, Vertex reported positive trial data from a candidate that could be a game changer. The company's gene-editing candidate for blood disorders produced positive results in follow up of at least three months.</p><p><blockquote>尽管如此，投资者担心Vertex正在努力向CF以外的地区扩张。最近的消息表明，这种观点可能过于悲观。今年，Vertex报告了一位可能改变游戏规则的候选人的积极试验数据。该公司针对血液疾病的基因编辑候选药物在至少三个月的随访中产生了积极的结果。</blockquote></p><p> Currently, treatment options for the disorders are limited. But Vertex's candidate is designed to be a one-time curative treatment. The company aims to file for regulatory approval by the end of next year.</p><p><blockquote>目前，这些疾病的治疗选择有限。但Vertex的候选药物旨在成为一次性治疗。该公司计划在明年年底前申请监管部门批准。</blockquote></p><p> At the same time, Vertex is moving other promising candidates through the pipeline. It recently reported positive phase 1/2 trial data from an investigational stem-cell-derived treatment for type 1 diabetes. The company also said itmade a \"breakthrough\"in work on a potential treatment for the 10% of CF patients who aren't candidates for its already commercialized CF drugs. Vertex's shares may not look very dynamic right now, but if all goes smoothly for even one of these pipeline programs, the shares could soar in the coming years.</p><p><blockquote>与此同时，Vertex正在通过管道输送其他有前途的候选人。它最近报告了一项研究性干细胞衍生治疗1型糖尿病的积极1/2期试验数据。该公司还表示，它在针对10%不适合其已商业化CF药物的CF患者的潜在治疗方面取得了“突破”。Vertex的股价目前可能看起来不是很有活力，但如果其中一个管道项目一切顺利，其股价可能会在未来几年飙升。</blockquote></p><p> Unlike the previous two stocks, <b>Etsy</b> is an online platform that brings together sellers of handcrafted goods with buyers. It's fun and easy to use -- for instance, you can explore goods from sellers anywhere in the world with just a click of the mouse.</p><p><blockquote>与前两只股票不同的是，<b>Etsy</b>是一个在线平台，将手工制品的卖家和买家聚集在一起。它既有趣又易于使用——例如，你只需点击一下鼠标，就可以探索世界上任何地方卖家的商品。</blockquote></p><p> Etsy benefited from the surge in online shopping during the pandemic. But e-commerce isn't a short-lived trend. Global retail e-commerce may reach $5.4 trillion next year from $4.28 trillion in 2020, according to Statista.</p><p><blockquote>Etsy受益于疫情期间在线购物的激增。但电子商务并不是一个短暂的趋势。根据Statista的数据，明年全球零售电子商务可能会从2020年的4.28万亿美元达到5.4万亿美元。</blockquote></p><p> Etsy's latest earnings report supports this idea. Gross merchandise sales (GMS) and its number of loyal customers continue to rise. GMS rose more than 17% to $3.1 billion in the quarter. And habitual buyers -- those who spent at least $200 in six or more days within the past year -- climbed 65%.</p><p><blockquote>Etsy最新的财报支持了这一观点。商品销售总额（GMS）及其忠实客户数量持续上升。GMS本季度增长超过17%，至31亿美元。习惯性买家——那些在过去一年中六天或更长时间内花费至少200美元的人——攀升了65%。</blockquote></p><p> Etsy's recent acquisitions of Depop, a fashion resale marketplace, and Elo7, a Brazilian marketplace for handcrafted goods, should help it to further expand its market andgrow earnings. And this means Etsy's share price could follow -- and make you richer over the coming five years.</p><p><blockquote>Etsy最近收购了时尚转售市场Depop和巴西手工制品市场Elo7，这应该有助于其进一步扩大市场并增加盈利。这意味着Etsy的股价可能会随之上涨，并让您在未来五年内变得更加富有。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Than Can Turn $10,000 Into $50,000 by 2025<blockquote>到2025年可以将10,000美元变成50,000美元的3只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Than Can Turn $10,000 Into $50,000 by 2025<blockquote>到2025年可以将10,000美元变成50,000美元的3只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-12 11:16</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul> <li>Teladoc’s revenue and patient visits this year show it isn't a pandemic-only stock.</li> <li>Vertex plans to file for regulatory approval next year of a potentially game-changing blood disorder candidate.</li> <li>Etsy’s recent acquisitions should help it to expand its reach and grow in the coming years.</li> </ul> A lot can happen in five years. And that's exactly why it's a great idea to hold stocks for that period of time. This way, you have the opportunity to benefit from a company's growing sales, new products, or expansion into additional markets. Often, a company's good news takes a while to translate into share gains.</p><p><blockquote><ul><li>Teladoc今年的收入和患者就诊次数表明，它并不是一只只针对大流行的股票。</li><li>Vertex计划明年向监管部门申请一种可能改变游戏规则的血液疾病候选药物的批准。</li><li>Etsy最近的收购应该有助于其扩大业务范围并在未来几年实现增长。</li></ul>五年内会发生很多事情。这就是为什么在这段时间内持有股票是个好主意。这样，你就有机会从公司不断增长的销售额、新产品或向其他市场的扩张中受益。通常，公司的好消息需要一段时间才能转化为股价上涨。</blockquote></p><p> The following two healthcare stocks and one consumer stock have what it takes to produce lasting revenue growth in the coming five years -- and eventually, major share-price gains. That means they very well might turn $10,000 into $50,000.</p><p><blockquote>以下两只医疗保健股和一只消费股有能力在未来五年内实现持久的收入增长，并最终实现股价大幅上涨。这意味着他们很可能会把10,000美元变成50,000美元。</blockquote></p><p> The pandemic equaled meteoric growth for <b>Teladoc Health</b></p><p><blockquote>这场大流行相当于<b>Teladoc健康</b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/016a56aa1f203a6ad80617c0119f66cf\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> As vaccinations took off and the pandemic eased, investors worried business at Teladoc would drop. And that's why the shares have suffered this year -- falling 28% so far.</p><p><blockquote>随着疫苗接种的开始和疫情的缓解，投资者担心Teladoc的业务会下降。这就是该股今年遭受重创的原因——迄今为止已下跌28%。</blockquote></p><p> But Teladoc is proving that it isn't a pandemic-only stock. People have returned to work, and healthcare facilities have returned to normal operations -- yet Teladoc's revenue and patient visits still are climbing.</p><p><blockquote>但Teladoc正在证明它不仅仅是一只只针对大流行的股票。人们已经重返工作岗位，医疗机构也已恢复正常运营，但Teladoc的收入和患者就诊人数仍在攀升。</blockquote></p><p> In the most recent earnings report, Teladoc said quarterly revenue rose 81% and patient visits increased 37%, surpassing 3.9 million. The company even increased the lower end of its annual revenue guidance. It expects a minimum of $2.015 billion in revenue this year, and next year's revenue may reach $2.6 billion.</p><p><blockquote>Teladoc在最新的收益报告中表示，季度收入增长了81%，患者访问量增长了37%，超过390万人次。该公司甚至提高了年度收入指引的下限。它预计今年的营收至少为20.15亿美元，明年的营收可能达到26亿美元。</blockquote></p><p> Teladoc's strength in chronic-care management should be a key element driving future patient loyalty and growth. Today, 24% of Teladoc's chronic-care members are enrolled in multiple programs. That number was only 8% a year ago.</p><p><blockquote>Teladoc在慢性护理管理方面的优势应该成为推动未来患者忠诚度和增长的关键因素。如今，Teladoc 24%的慢性护理会员参加了多个计划。一年前这个数字只有8%。</blockquote></p><p> All of these numbers together show us that Teladoc's success last year wasn't just a one-off. Instead, it was the first chapter in a much longer story.</p><p><blockquote>所有这些数字加在一起向我们表明，Teladoc去年的成功不仅仅是一次性的。相反，这是一个更长故事的第一章。</blockquote></p><p> <b>Vertex Pharmaceuticals</b></p><p><blockquote><b>顶点制药</b></blockquote></p><p> Why should we be optimistic about Vertex? First, the company makes billions of dollars in revenue and profit annually from its portfolio of cystic fibrosis (CF) drugs.</p><p><blockquote>为什么要看好Vertex？首先，该公司每年从其囊性纤维化(CF)药物组合中获得数十亿美元的收入和利润。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/86204fd33911338b208591a6f1f67d95\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> It's the worldwide CF leader and expects that to continue until at least the late 2030s.</p><p><blockquote>它是全球CF领导者，预计这种情况至少会持续到2030年代末。</blockquote></p><p> That said, investors worry Vertex is struggling to expand beyond CF. Recent news indicates this view may be overly pessimistic. This year, Vertex reported positive trial data from a candidate that could be a game changer. The company's gene-editing candidate for blood disorders produced positive results in follow up of at least three months.</p><p><blockquote>尽管如此，投资者担心Vertex正在努力向CF以外的地区扩张。最近的消息表明，这种观点可能过于悲观。今年，Vertex报告了一位可能改变游戏规则的候选人的积极试验数据。该公司针对血液疾病的基因编辑候选药物在至少三个月的随访中产生了积极的结果。</blockquote></p><p> Currently, treatment options for the disorders are limited. But Vertex's candidate is designed to be a one-time curative treatment. The company aims to file for regulatory approval by the end of next year.</p><p><blockquote>目前，这些疾病的治疗选择有限。但Vertex的候选药物旨在成为一次性治疗。该公司计划在明年年底前申请监管部门批准。</blockquote></p><p> At the same time, Vertex is moving other promising candidates through the pipeline. It recently reported positive phase 1/2 trial data from an investigational stem-cell-derived treatment for type 1 diabetes. The company also said itmade a \"breakthrough\"in work on a potential treatment for the 10% of CF patients who aren't candidates for its already commercialized CF drugs. Vertex's shares may not look very dynamic right now, but if all goes smoothly for even one of these pipeline programs, the shares could soar in the coming years.</p><p><blockquote>与此同时，Vertex正在通过管道输送其他有前途的候选人。它最近报告了一项研究性干细胞衍生治疗1型糖尿病的积极1/2期试验数据。该公司还表示，它在针对10%不适合其已商业化CF药物的CF患者的潜在治疗方面取得了“突破”。Vertex的股价目前可能看起来不是很有活力，但如果其中一个管道项目一切顺利，其股价可能会在未来几年飙升。</blockquote></p><p> Unlike the previous two stocks, <b>Etsy</b> is an online platform that brings together sellers of handcrafted goods with buyers. It's fun and easy to use -- for instance, you can explore goods from sellers anywhere in the world with just a click of the mouse.</p><p><blockquote>与前两只股票不同的是，<b>Etsy</b>是一个在线平台，将手工制品的卖家和买家聚集在一起。它既有趣又易于使用——例如，你只需点击一下鼠标，就可以探索世界上任何地方卖家的商品。</blockquote></p><p> Etsy benefited from the surge in online shopping during the pandemic. But e-commerce isn't a short-lived trend. Global retail e-commerce may reach $5.4 trillion next year from $4.28 trillion in 2020, according to Statista.</p><p><blockquote>Etsy受益于疫情期间在线购物的激增。但电子商务并不是一个短暂的趋势。根据Statista的数据，明年全球零售电子商务可能会从2020年的4.28万亿美元达到5.4万亿美元。</blockquote></p><p> Etsy's latest earnings report supports this idea. Gross merchandise sales (GMS) and its number of loyal customers continue to rise. GMS rose more than 17% to $3.1 billion in the quarter. And habitual buyers -- those who spent at least $200 in six or more days within the past year -- climbed 65%.</p><p><blockquote>Etsy最新的财报支持了这一观点。商品销售总额（GMS）及其忠实客户数量持续上升。GMS本季度增长超过17%，至31亿美元。习惯性买家——那些在过去一年中六天或更长时间内花费至少200美元的人——攀升了65%。</blockquote></p><p> Etsy's recent acquisitions of Depop, a fashion resale marketplace, and Elo7, a Brazilian marketplace for handcrafted goods, should help it to further expand its market andgrow earnings. And this means Etsy's share price could follow -- and make you richer over the coming five years.</p><p><blockquote>Etsy最近收购了时尚转售市场Depop和巴西手工制品市场Elo7，这应该有助于其进一步扩大市场并增加盈利。这意味着Etsy的股价可能会随之上涨，并让您在未来五年内变得更加富有。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/11/11/3-stocks-than-can-turn-10000-into-50000-by-2025/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","ETSY":"Etsy, Inc.","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2021/11/11/3-stocks-than-can-turn-10000-into-50000-by-2025/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148636425","content_text":"Key Points\n\nTeladoc’s revenue and patient visits this year show it isn't a pandemic-only stock.\nVertex plans to file for regulatory approval next year of a potentially game-changing blood disorder candidate.\nEtsy’s recent acquisitions should help it to expand its reach and grow in the coming years.\n\nA lot can happen in five years. And that's exactly why it's a great idea to hold stocks for that period of time. This way, you have the opportunity to benefit from a company's growing sales, new products, or expansion into additional markets. Often, a company's good news takes a while to translate into share gains.\nThe following two healthcare stocks and one consumer stock have what it takes to produce lasting revenue growth in the coming five years -- and eventually, major share-price gains. That means they very well might turn $10,000 into $50,000.\nThe pandemic equaled meteoric growth for Teladoc Health\n\nAs vaccinations took off and the pandemic eased, investors worried business at Teladoc would drop. And that's why the shares have suffered this year -- falling 28% so far.\nBut Teladoc is proving that it isn't a pandemic-only stock. People have returned to work, and healthcare facilities have returned to normal operations -- yet Teladoc's revenue and patient visits still are climbing.\nIn the most recent earnings report, Teladoc said quarterly revenue rose 81% and patient visits increased 37%, surpassing 3.9 million. The company even increased the lower end of its annual revenue guidance. It expects a minimum of $2.015 billion in revenue this year, and next year's revenue may reach $2.6 billion.\nTeladoc's strength in chronic-care management should be a key element driving future patient loyalty and growth. Today, 24% of Teladoc's chronic-care members are enrolled in multiple programs. That number was only 8% a year ago.\nAll of these numbers together show us that Teladoc's success last year wasn't just a one-off. Instead, it was the first chapter in a much longer story.\nVertex Pharmaceuticals\nWhy should we be optimistic about Vertex? First, the company makes billions of dollars in revenue and profit annually from its portfolio of cystic fibrosis (CF) drugs.\n\nIt's the worldwide CF leader and expects that to continue until at least the late 2030s.\nThat said, investors worry Vertex is struggling to expand beyond CF. Recent news indicates this view may be overly pessimistic. This year, Vertex reported positive trial data from a candidate that could be a game changer. The company's gene-editing candidate for blood disorders produced positive results in follow up of at least three months.\nCurrently, treatment options for the disorders are limited. But Vertex's candidate is designed to be a one-time curative treatment. The company aims to file for regulatory approval by the end of next year.\nAt the same time, Vertex is moving other promising candidates through the pipeline. It recently reported positive phase 1/2 trial data from an investigational stem-cell-derived treatment for type 1 diabetes. The company also said itmade a \"breakthrough\"in work on a potential treatment for the 10% of CF patients who aren't candidates for its already commercialized CF drugs. Vertex's shares may not look very dynamic right now, but if all goes smoothly for even one of these pipeline programs, the shares could soar in the coming years.\nUnlike the previous two stocks, Etsy is an online platform that brings together sellers of handcrafted goods with buyers. It's fun and easy to use -- for instance, you can explore goods from sellers anywhere in the world with just a click of the mouse.\nEtsy benefited from the surge in online shopping during the pandemic. But e-commerce isn't a short-lived trend. Global retail e-commerce may reach $5.4 trillion next year from $4.28 trillion in 2020, according to Statista.\nEtsy's latest earnings report supports this idea. Gross merchandise sales (GMS) and its number of loyal customers continue to rise. GMS rose more than 17% to $3.1 billion in the quarter. And habitual buyers -- those who spent at least $200 in six or more days within the past year -- climbed 65%.\nEtsy's recent acquisitions of Depop, a fashion resale marketplace, and Elo7, a Brazilian marketplace for handcrafted goods, should help it to further expand its market andgrow earnings. And this means Etsy's share price could follow -- and make you richer over the coming five years.","news_type":1,"symbols_score_info":{"ETSY":0.9,"VRTX":0.9,"TDOC":0.9}},"isVote":1,"tweetType":1,"viewCount":575,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/879111551"}
精彩评论